About
Technology
Issues
FAQ
Title
Abstract
Text
Figure Captions
Table Cells
Section Titles
Keywords
Subjects
Authors
From
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
To
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
All Types
Articles
Communications
Reviews
Discussions
Case Reports
Chapters
Books
News
Editorials
Order By
Order By Year ASC
Order By Year DESC
Order By Citations ASC
Order By Citations DESC
Go
Scientometrics
Impact Factor
Discipline Ranks
H-Index
G-Index
Articles
Citations
Article Citations
Citation Distribution
Search This Journal
Overviews
Top Institutions
Top Schools
Top Authors
Prolific Authors
Top Articles
exaly
›
Journals
›
Blood Cancer Journal
›
Top Articles
Blood Cancer Journal
Hematology
,
Oncology
7
(top 2%)
Impact Factor
7.7
(top 2%)
extended IF
64
(top 6%)
H-Index
2K
authors
1.3K
papers
24.1K
citations
2K
citing journals
18.9K
citing authors
Most Cited Articles of Blood Cancer Journal
Title
Year
Citations
'Acute myeloid leukemia: a comprehensive review and 2016 update'
2016
542
Acute lymphoblastic leukemia: a comprehensive review and 2017 update
2017
436
The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion
2018
221
Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia
2014
183
Acute promyelocytic leukemia: where did we start, where are we now, and the future
2015
164
Pathogenesis of bone disease in multiple myeloma: from bench to bedside
2018
144
Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts
2016
130
High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites
2013
130
Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors
2015
129
Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study
2019
126
Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia
2015
123
Interpretation of cytogenetic results in multiple myeloma for clinical practice
2015
121
CAR-T cell therapy: current limitations and potential strategies
2021
119
Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria
2018
115
Identification of Toyocamycin, an agent cytotoxic for multiple myeloma cells, as a potent inhibitor of ER stress-induced XBP1 mRNA splicing
2012
115
Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients
2014
114
Long-term complications and side effects after allogeneic hematopoietic stem cell transplantation: an update
2011
114
Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4
2015
113
CircRNAs in hematopoiesis and hematological malignancies
2016
105
PD-1 expression defines two distinct T-cell sub-populations in follicular lymphoma that differentially impact patient survival
2015
102
Myeloma cells suppress osteoblasts through sclerostin secretion
2011
100
High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma
2017
99
Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting
2018
97
TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution
2015
95
PD-1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation
2015
90
0
1
2
next
How are inpact factors calculated?
The impact factor (IF) is calculated by counting citations from peer-reviewed journals only.
extended IF
also counts citations from books and conference papers. However, no patent, abstract, working papers, online documents, etc., are covered.
site/software ©
exaly
; All materials licenced under
CC by-SA
.